Innovent Biologics Inc banner

Innovent Biologics Inc
HKEX:1801

Watchlist Manager
Innovent Biologics Inc Logo
Innovent Biologics Inc
HKEX:1801
Watchlist
Price: 81.9 HKD -0.79%
Market Cap: HK$142.1B

Wall Street
Price Targets

Price Targets Summary
Innovent Biologics Inc

Wall Street analysts forecast Innovent Biologics Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Innovent Biologics Inc is 113.4 HKD with a low forecast of 64.16 HKD and a high forecast of 144.27 HKD.

Lowest
Price Target
64.16 HKD
22% Downside
Average
Price Target
113.4 HKD
38% Upside
Highest
Price Target
144.27 HKD
76% Upside
Innovent Biologics Inc Competitors:
Price Targets
WINA
Winmark Corp
29% Upside
HCAT
Health Catalyst Inc
259% Upside

Revenue
Forecast

144% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
144% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

For the last 7 years the compound annual growth rate for Innovent Biologics Inc's revenue is 144%. The projected CAGR for the next 4 years is 30%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
16%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
16%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Innovent Biologics Inc's stock price target?
Price Target
113.4 HKD

According to Wall Street analysts, the average 1-year price target for Innovent Biologics Inc is 113.4 HKD with a low forecast of 64.16 HKD and a high forecast of 144.27 HKD.

What is Innovent Biologics Inc's Revenue forecast?
Projected CAGR
30%

For the last 7 years the compound annual growth rate for Innovent Biologics Inc's revenue is 144%. The projected CAGR for the next 4 years is 30%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett